PTC Therapeutics, Inc. (PTCT) Earnings

Management highlights

- Suffiance (PKU Therapy) Global Launch - Achieved 100% penetration of all U.S. Centers of Excellence, with broad uptake across all disease severities, age groups, and treatment backgrounds including naive patients, prior therapy failures, and patients switching from existing treatments. Adherence rates are strong, with reported patient benefits including phenylalanine reduction, diet liberalization, and improvements in mood, cognition, and quality of life. - Japan launch began ramping in Q2 2026, with early uptake exceeding internal expectations, pricing on par with the U.S. locked in for 10 years, and broad uptake across patient segments. Early access programs are active across multiple European countries (France, Italy, Spain, Germany) with accelerating demand, and positive regulatory progress in Brazil where Suffiance received the highest therapeutic benefit classification. - 17 oral and poster presentations of Suffiance clinical and real-world data are planned for the upcoming SSIEM global metabolism conference, including new data showing many patients achieve rapid blood phenylalanine normalization. - Pipeline Progress - Vodafone (Vodoplarn) for Huntington's Disease: Positive 24-month interim data from the PivotHD extension study showed a 52% average slowing of disease progression relative to natural history in the 10mg Stage 2 cohort, with a sustained favorable safety profile. Novartis has initiated enrollment for the global Phase 3 InvestHD study (expected to enroll ~770 patients), and PTC and Novartis plan to discuss the 24-month data and potential accelerated approval pathways with the FDA in H2 2026. - Vatiquinone for Friedreich's Ataxia: Finalized the PROVE-FA open-label trial protocol with a natural history comparator to support NDA resubmission, with trial initiation planned for Q3 2026, enrolling ~120 patients aged 7 to 21. - Early Pipeline: Phase 1 study of PTC612 (oral NLRP3 inhibitor) is ongoing, with multiple single and multiple ascending dose cohorts completed, and an additional cohort of patients with obesity and cardiovascular disease planned to generate early PKPD data. Phase IIa study of PTC844 (next-generation DHO-DH inhibitor) is planned for Q3 2026 to assess biomarker effects. PTC303, the MSH3 splicing program for triplet repeat expansion diseases (including Huntington's and myotonic dystrophy), has selected a development candidate and is on track to enter the clinic in 2027. - Financial and Operational Highlights - Ended Q2 2026 with $2.23 billion in cash and marketable securities, up from $1.95 billion at the end of 2025. Successfully refinanced the majority of 2026 convertible notes to new 2031 notes with a 0% coupon and 40% conversion premium. - Mature brands continue to deliver durable revenue despite generic competition, with ongoing brand loyalty supported by PTC's patient support programs.

Guidance

- Management raised full-year 2026 product revenue guidance to $850 million to $950 million, and updated total revenue guidance to $1.18 billion to $1.28 billion, driven by stronger-than-expected Suffiance growth and better-than-expected durability of the DMD franchise. - The company remains on track to potentially achieve cash flow breakeven in 2026. - Suffiance is expected to see steady growth in the U.S. and accelerating growth in international markets through the second half of 2026 and into 2027, with management maintaining confidence in a long-term $2 billion-plus global peak revenue opportunity. - The company expects to launch Suffiance in 20 to 30 global markets by the end of 2026, with additional markets to follow in 2027 and beyond.

Segment performance

For Q2 2026, total revenue was $361 million, with total product and royalty revenue of $310 million and net product revenue of $239 million (representing over 100% year-over-year growth from Q2 2025's $118 million net product revenue). - Suffiance: Net product revenue of $151 million, accounting for 63.2% of total net product revenue, growing 21% quarter-over-quarter. There were 1,647 global commercial patients on Suffiance as of June 30, 2026. - DMD Franchise: Combined net product revenue of $67 million, accounting for 28.0% of total net product revenue. This includes Translarna at $42 million and Emflaza at $25 million. - Royalty Revenue: Royalty revenue from Roche was $71 million, driven by Roche's $628 million Q2 global revenue.

Risks & headwinds

- All forward-looking statements, including launch, pipeline, and profitability expectations, are subject to risks and uncertainties that could cause actual results to differ materially, detailed in the company's SEC filings. - The DMD franchise faces ongoing headwinds from generic competition for Emflaza, which could impact future revenue contributions. - International pricing and reimbursement approvals across European and other global markets are still ongoing, with final outcomes and timelines uncertain. - Pipeline programs (including clinical trials for Vodafone, vatiquinone, and early-stage assets) face inherent clinical and regulatory risks that could prevent or delay approval or commercialization.

Analyst Q&A

• Q: The analyst estimates ~10% U.S. patient penetration so far, and asks what the company sees for long-term peak penetration, and what key goals the company has for upcoming medical conferences. /

  A: Management confirms it is very early in the launch, with 100% of U.S. Centers of Excellence now prescribing, giving a strong base for deeper penetration going forward. Historically, ~70% of patients have tried older PKU therapy KUVAN, and Suffiance is also drawing patients from the 30% that have never tried prior therapy, leaving a very large patient population still untapped. Upcoming conferences aim to build awareness among untreated patients, reinforce that Suffiance delivers benefits across all patient types including classical, BH4-non-responsive patients, and demonstrate superior results for patients switching from existing therapies to drive higher trial and adoption rates. Discontinuation is defined as 60+ days without a prescription renewal, and the current 20% discontinuation rate is low for an early launch, with prescription renewal rates over 90%.

• Q: How do you reconcile strong new patient growth with slower revenue growth, and what are the goals of the upcoming FDA discussion for Vodafone? /

  A: Variations between patient growth and revenue stem from multiple factors including varying patient dosage needs based on weight, differing timing of patient entries into the quarter, and variable reimbursement timelines. Consistent patient growth is expected to translate to continued revenue growth over time. The primary goal of the H2 2026 FDA discussion is to explore the potential for accelerated approval of Vodafone based on the existing 24-month interim data. Management notes the dose-dependent clinical effect, proven target engagement, strong safety profile, and ongoing Phase 3 study support a productive discussion, with the goal of accelerating patient access to this potential therapy for Huntington's disease.

• Q: What is the long-term expected U.S. vs ex-U.S. revenue split for Suffiance, and what is the company's current appetite for business development? /

  A: While the U.S. will likely remain the majority revenue contributor long-term, ex-U.S. markets are expected to become a significant growing contributor to Suffiance revenue, supported by strong early uptake and attractive pricing in markets like Japan. PTC ended the quarter with $2.2 billion in cash, maintains a disciplined approach to BD, and is not looking to over-lever the company. The company is primarily focused on not distracting from its core Suffiance launch, but is actively evaluating complementary rare disease opportunities, including late-stage or commercial assets that can leverage PTC's existing global commercial infrastructure.

• Q: What are your thoughts on Roche discontinuing the tominersen Huntington's disease study, and is PTC-303 for Huntington's intended as monotherapy or combination therapy with Vodafone? /

  A: Management views tominersen's failure as specific to the ASO modality, which caused significant CSF inflammation that confounded clinical efficacy signals, rather than a reflection of the HTT lowering approach that Vodafone uses. PTC's oral small molecule approach avoids these inflammatory issues, with full brain biodistribution and a manageable safety profile. PTC-303 (the MSH3 splicing therapy) can work well in combination with Vodafone, and also has potential as a monotherapy, particularly for juvenile Huntington's disease which is characterized by rapid somatic expansion that MSH3 targeting addresses. PTC-303 is on track to enter clinical trials in 2027.